121 related articles for article (PubMed ID: 36731722)
1. Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension.
Abdulkareem AO; Tiwari P; Lone ZR; Iqbal H; Gupta S; Jha RK; Chanda D; Jagavelu K; Hanif K
Eur J Pharmacol; 2023 Mar; 943():175558. PubMed ID: 36731722
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
3. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
4. Modulation of estrogen action during preimplantation period and in immature estradiol-primed rat uterus by anti-implantation agent, ormeloxifene.
Dwivedi A; Basu R; Chowdhury SR; Goyal N
Contraception; 2005 Jun; 71(6):458-64. PubMed ID: 15914137
[TBL] [Abstract][Full Text] [Related]
5. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Zhang X; Zhu H; Jackson EK; Rafikova O; Petrusevska G
Vascul Pharmacol; 2008; 48(4-6):174-83. PubMed ID: 18373958
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
Jin H; Jiao Y; Guo L; Ma Y; Zhao R; Li X; Shen L; Zhou Z; Kim SC; Liu J
Int J Mol Med; 2021 Feb; 47(2):595-606. PubMed ID: 33416126
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycitric Acid Tripotassium Hydrate Attenuates Monocrotaline and Hypoxia-Induced Pulmonary Hypertension in Rats.
Wang S; Li H; Liu Q; Ma H; Huang L; Yu L; Wu Z
Int Heart J; 2024; 65(2):318-328. PubMed ID: 38556339
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
9. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways.
Yuan P; Wu WH; Gao L; Zheng ZQ; Liu D; Mei HY; Zhang ZL; Jing ZC
Eur Respir J; 2013 May; 41(5):1116-25. PubMed ID: 22936708
[TBL] [Abstract][Full Text] [Related]
10. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
11. Endogenous estrogen attenuates hypoxia-induced pulmonary hypertension by inhibiting pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cells proliferation.
Xu D; Niu W; Luo Y; Zhang B; Liu M; Dong H; Liu Y; Li Z
Int J Med Sci; 2013; 10(6):771-81. PubMed ID: 23630443
[TBL] [Abstract][Full Text] [Related]
12. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
Horstman DJ; Frank DU; Rich GF
Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
[TBL] [Abstract][Full Text] [Related]
13. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.
Lahm T; Albrecht M; Fisher AJ; Selej M; Patel NG; Brown JA; Justice MJ; Brown MB; Van Demark M; Trulock KM; Dieudonne D; Reddy JG; Presson RG; Petrache I
Am J Respir Crit Care Med; 2012 May; 185(9):965-80. PubMed ID: 22383500
[TBL] [Abstract][Full Text] [Related]
14. Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions.
Shafiq M; Lone ZR; Bharati P; Mahapatra S; Rai P; Khandelwal N; Gaikwad AN; Jagavelu K; Hanif K
Pulm Pharmacol Ther; 2022 Oct; 76():102156. PubMed ID: 36030026
[TBL] [Abstract][Full Text] [Related]
15. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
16. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats.
Tofovic SP; Zhang X; Jackson EK; Zhu H; Petrusevska G
Vascul Pharmacol; 2009; 51(2-3):190-7. PubMed ID: 19540933
[TBL] [Abstract][Full Text] [Related]
17. Influence of estrogen on pulmonary arterial hypertension: role of oxidative stress.
Siqueira R; Campos C; Colombo R; Becker CU; Fernandes TR; Araújo AS; Belló-Klein A
Cell Biochem Funct; 2011 Oct; 29(7):543-8. PubMed ID: 21989892
[TBL] [Abstract][Full Text] [Related]
18. Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen-deficient rats.
Tofovic PS; Zhang X; Petrusevska G
Prilozi; 2009 Jul; 30(1):25-44. PubMed ID: 19736529
[TBL] [Abstract][Full Text] [Related]
19. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
